[1] |
MAEDA T, ABE M, KURISU K, et al. Molecular cloning and characterization of a novel gene, CORS26, encoding a putative secretory protein and its possible involvement in skeletal development[J]. J Biol Chem, 2001, 276(5):3628-3634.
|
[2] |
SVESTAK M, SPOROVA L, HEJDUK P, et al. Collagenous repeat-containing sequence of 26 kDa protein - a newly discovered adipokine - sensu lato - A minireview[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010, 154(3):199-202.
|
[3] |
YARIBEYGI H, RASHIDFARROKHI F, ATKIN S, et al. C1q/TNF-related protein-3 and glucose homeostasis[J]. Diabetes Metab Syndr, 2019, 13(3):1923-1927.
|
[4] |
PETERSON J M, WEI Z K, WONG G W. C1q/TNF-related Protein-3(CTRP3), a novel adipokine that regulates hepatic glucose output[J]. J Biol Chem, 2010, 285(51):39691-39701.
|
[5] |
张城林, 吴立玲, 李丽. 补体C1q/肿瘤坏死因子相关蛋白3的研究进展[J]. 生理学报, 2017, 69(5):666-676.ZHANG C L, WU L L, LI L. Research progress of complement- C1q/tumor necrosis factor-related protein 3[J]. Acta Physiologica Sinica, 2017, 69(5):666-676. (in Chinese)
|
[6] |
DENG W Q, LI C Y, ZHANG Y P, et al. Serum C1q/TNF-related protein-3(CTRP3) levels are decreased in obesity and hypertension and are negatively correlated with parameters of insulin resistance[J]. Diabetol Metab Syndr, 2015, 7(1):33.
|
[7] |
WEI H L, QU H, WANG H, et al. Plasma C1q/TNF-Related Protein-3(CTRP-3) and High-Mobility Group Box-1(HMGB-1) Concentrations in Subjects with Prediabetes and Type 2 Diabetes[J]. J Diabetes Res, 2016, 2016:9438760.
|
[8] |
GUO B, ZHUANG T T, XU F, et al. New Insights Into Implications of CTRP3 in Obesity, Metabolic Dysfunction, and Cardiovascular Diseases:Potential of Therapeutic Interventions[J]. Front Physiol, 2020, 11:570270.
|
[9] |
CHEN T, WANG F Y, CHU Z Y, et al. Serum CTRP3 levels in obese children:A potential protective adipokine of obesity, insulin sensitivity and pancreatic β cell function[J]. Diabetes Metab Syndr Obes, 2019, 12:1923-1930.
|
[10] |
NISHIMOTO H, YAMAMOTO A, FURUKAWA S, et al. C1q/TNF-related protein 3 expression and effects on adipocyte differentiation of 3T3-L1 cells[J]. Cell Biol Int, 2017, 41(2):197-203.
|
[11] |
TROGEN G, BACON J, LI Y, et al. Transgenic overexpression of CTRP3 prevents alcohol-induced hepatic triglyceride accumulation[J]. Am J Physiol Endocrinol Metab, 2018, 315(5):E949-E960.
|
[12] |
LI X, JIANG L, YANG M, et al. CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes[J]. Endocr J, 2014, 61(12):1153-1162.
|
[13] |
ZHAO G, ZHANG L W, QIAN D J, et al. miR-495-3p inhibits the cell proliferation, invasion and migration of osteosarcoma by targeting C1q/TNF-related protein 3[J]. Onco Targets Ther, 2019, 12:6133-6143.
|
[14] |
ZHANG K L, DONG C, CHEN M, et al. Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma[J]. Theranostics, 2020, 10(1):411-425.
|
[15] |
WANG H, GUO Y, MI N, et al. miR-101-3p and miR-199b-5p promote cell apoptosis in oral cancer by targeting BICC1[J]. Mol Cell Probes, 2020, 52:101567.
|
[16] |
GUAN H T, DAI Z J, MA Y G, et al. MicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancer[J]. Int J Mol Med, 2016, 37(6):1643-1651.
|
[17] |
HIGUCHI C, NAKATSUKA A, EGUCHI J, et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes[J]. Metabolism, 2015, 64(4):489-497.
|
[18] |
ORTEGA F J, MORENO-NAVARRETE J M, PARDO G, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation[J]. PLoS One, 2010, 5(2):e9022.
|
[19] |
KAJIMOTO K. MicroRNA and 3T3-L1 pre-adipocyte differentiation[J]. RNA, 2006, 12(9):1626-1632.
|
[20] |
BLASZCZAK A M, JALILVAND A, HSUEH W A. Adipocytes, innate immunity and obesity:A mini-review[J]. Front Immunol, 2021, 12:650768.
|
[21] |
MAEDA T, WAKISAKA S. Deficiency of C1q/TNF-related protein 3(CTRP3) decreases adipose tissue weight in diet-induced obesity mice[J]. Mol Biol Rep, 2020, 47(11):9219-9224.
|
[22] |
BONNAL S C, LÓPEZ-OREJA I, VALCÁRCEL J. Roles and mechanisms of alternative splicing in cancer-implications for care[J]. Nat Rev Clin Oncol, 2020, 17(8):457-474.
|
[23] |
BLENCOWE B J. Alternative splicing:new insights from global analyses[J]. Cell, 2006, 126(1):37-47.
|
[24] |
PARK J W, FU S Y, HUANG B R, et al. Alternative splicing in mesenchymal stem cell differentiation[J]. Stem Cells, 2020, 38(10):1229-1240.
|
[25] |
MODREK B, LEE C. A genomic view of alternative splicing[J]. Nat Genet, 2002, 30(1):13-19.
|
[26] |
NILSEN T W, GRAVELEY B R. Expansion of the eukaryotic proteome by alternative splicing[J]. Nature, 2010, 463(7280):457-463.
|
[27] |
LUCO R F, ALLO M, SCHOR I E, et al. Epigenetics in alternative pre-mRNA splicing[J]. Cell, 2011, 144(1):16-26.
|
[28] |
MAKAROV E M, SHTAM T A, KOVALEV R A, et al. The rare nonsense mutation in p53 triggers alternative splicing to produce a protein capable of inducing apoptosis[J]. PLoS One, 2017, 12(9):e0185126.
|
[29] |
WANG H, HE K, ZENG X H, et al. Isolation and identification of goose skeletal muscle satellite cells and preliminary study on the function of C1q and tumor necrosis factor-related protein 3 gene[J]. Anim Biosci, 2021, 34(6):1078-1087.
|
[30] |
FENG H J, QIN Z Y, ZHANG X G. Opportunities and methods for studying alternative splicing in cancer with RNA-Seq[J]. Cancer Lett, 2013, 340(2):179-191.
|
[31] |
WANG H R, MENG Y K, CUI Q J, et al. MiR-101 targets the EZH2/Wnt/β-Catenin the pathway to promote the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells[J]. Sci Rep, 2016, 6:36988.
|